Seeking Alpha
 

Enzon Pharmaceuticals, Inc. (ENZN)

- NASDAQ
  • Apr. 24, 2013, 11:27 AM
    Enzon Pharmaceuticals (ENZN -11.5%) flips an early pre-market gain to trade lower after the company unveiled a special dividend, a move that comes as the biopharmaceutical company concluded an earlier review of strategic alternatives and a workforce reduction. Late last year, Carl Icahn divulged a 13.3% stake in the company, and was taking an active interest in its operations and direction.
    | Apr. 24, 2013, 11:27 AM | Comment!
  • Apr. 23, 2013, 6:38 PM
    Enzon Pharmaceuticals (ENZN) declares special dividend of $1.60/share. For shareholders of record May 07. Payable June 04. Ex-div date May 03. (PR)
    | Apr. 23, 2013, 6:38 PM | 8 Comments
  • Apr. 23, 2013, 5:48 PM
    After-hours top gainers, as of 5:15 p.m.: IRBT +14%. ENZN +7%. YUM +6%. BRCM +5%. AAPL +5%.
    After-hours top losers: VOCS -30%. UIS -16%. DV -12%. AWAY -8%. PNRA -6%.
    | Apr. 23, 2013, 5:48 PM | Comment!
  • Mar. 27, 2013, 10:42 AM
    Enzon Pharmaceuticals (ENZN -2.8%) hits a new 52-week low after disclosing in a regulatory filing late yesterday that it's reducing its workforce from 19 employees to 12. It expects to incur about $1.3M in charges related to the reduction in force, due to cash expenditures for one-time employee termination benefits and associated costs. The company expects to record the charges and complete the reduction by the end of Q1.
    | Mar. 27, 2013, 10:42 AM | 1 Comment
  • Mar. 19, 2013, 6:39 AM
    Enzon Pharmaceuticals (ENZN): Q4 EPS of -$0.11. Revenue of $10.6M. (PR)
    | Mar. 19, 2013, 6:39 AM | Comment!
  • Dec. 17, 2012, 10:33 AM
    Shares of Enzon Pharmaceuticals (ENZN) have resumed trading following an earlier halt, and the shares are currently up 5.4%. Carl Icahn has a 13.29% stake in Enzon, and disclosed in November that he and his associates wanted to discuss the operations and direction of the company.
    | Dec. 17, 2012, 10:33 AM | Comment!
  • Dec. 17, 2012, 9:10 AM
    Premarket gainers: JVA +12%. ENZN +10%. CBMX +10%. LXRX +9%. TROX +6%. CTIC +5%.
    Losers: NBG -13%. CLWR -11%. SQNM -6%.
    | Dec. 17, 2012, 9:10 AM | Comment!
  • Dec. 17, 2012, 7:28 AM
    Enzon Pharmaceuticals (ENZN) halts clinical development and has hired Lazard to explore a sale of the company. The move comes about 2 weeks after Carl Icahn renewed his push for a change in direction. Shares halted. (PR)
    | Dec. 17, 2012, 7:28 AM | Comment!
  • Dec. 6, 2012, 12:45 PM
    Midday top 10 gainers: BSDM +28%. EPHC +27%. MBLX +22%. INPH +18%. NVGN +18%. UEPS +17%. HITK +13%. CZR +11%. MITK +11%. CVO +11%.
    Midday top 10 Losers: ENZN -30%. TIGR -19%. SCMR -17%. NBY -16%. LFVN -14%. WEBM -14%. SNFCA -13%. KBW -13%. VRA -12%. HF -11%.
    | Dec. 6, 2012, 12:45 PM | Comment!
  • Dec. 6, 2012, 9:10 AM
    Premarket gainers: WLT +7%. ZNGA +6%. AKAM +5%.
    Losers: ENZN -28%. VRA -10%. MW -10%. COST -7%. ERJ -6%. LFVN -6%. LVS -5%.
     
    | Dec. 6, 2012, 9:10 AM | Comment!
  • Nov. 29, 2012, 5:34 PM
    Enzon Pharmaceuticals (ENZN) declares special dividend of $2.00/share. For shareholders of record Dec 10. Payable Dec 21. Ex-div date Dec 06. (PR)
    | Nov. 29, 2012, 5:34 PM | Comment!
  • Nov. 28, 2012, 3:29 PM
    Enzon Pharmaceuticals (ENZN -0.6%) slip after activist investor Carl Icahn files an amended 13D requesting a discussion on the company's operations and direction, as well as the it's plans to preserve shareholder value.
    | Nov. 28, 2012, 3:29 PM | Comment!
  • Feb. 28, 2012, 5:42 PM
    Enzon Pharmaceuticals (ENZN) discloses it has appointed Icahn Capital's George Hebard to a new board seat. Carl Icahn has long pushed for a management overhaul at Enzon.
    | Feb. 28, 2012, 5:42 PM | Comment!
  • Dec. 16, 2010, 9:00 AM
    Premarket gainers: CUR +11%. CCME +9%. UEC +7%. VG +7%. ENZN +7%. NVAX +6%. ERIC +4%. ARO +4%. MORT +4%. PCBC +4%. MCP +4%.
    Losers: RGS -8%.
    | Dec. 16, 2010, 9:00 AM | Comment!
  • Nov. 9, 2009, 8:33 AM
    Enzon Pharmaceuticals (ENZN) to sell its specialty pharmaceutical business to the sigma-tau Group for $300M plus another $27M if it hits certain milestones. ENZN will also retain royalties of 5-10%on incremental net sales above a baseline amount. ENZN is halted.
    | Nov. 9, 2009, 8:33 AM | Comment!
  • Oct. 22, 2009, 1:56 PM
    Why aren't you blogging, Carl Icahn? "I've been sort of busy. And right now, with the market up, there's not as much interest in corporate governance like there was a couple of months ago." Damien Park notes Carl's been among the most active of activists, seeking board seats at Enzon Pharmaceuticals (ENZN), Biogen (BIIB), Amylin (AMLN) and Lions Gate (LGF), and contuining to pester Yahoo (YHOO).
    | Oct. 22, 2009, 1:56 PM | 1 Comment
Visit Seeking Alpha's
ENZN vs. ETF Alternatives
Company Description
Enzon Pharmaceuticals Inc is related to sales of drugs by various companies. It generates revenues from the sales of products namely, PegIntron, Sylatron, Macugen and CIMZIA.
Sector: Healthcare
Industry: Biotechnology
Country: United States